The Israeli-based company has developed a proprietary RNAi nanoparticle formulation that triggers a cellular reaction to disable viral infections, which can be delivered via feed or immersion to improve resistance against viral diseases that attack shrimp and other aquaculture species. ViAqua Therapeutics aims to provide effective and affordable health management solutions for aquaculture, with their first product being a novel oral delivery platform designed to deliver RNA-induced resistance to white spot shrimp virus, co-developed with Skretting.